Proteinase treatment of intact hepatic mitochondria has differential effects on inhibition of carnitine palmitoyltransferase by different inhibitors.
Proteolysis of intact mitochondria by Nagarse (subtilisin BPN') and papain resulted in limited loss of activity of the outer-membrane carnitine palmitoyltransferase, but much greater loss of sensitivity to inhibition by malonyl-CoA. In contrast with a previous report [Murthy & Pande (1987) Proc. Natl. Acad. Sci. U.S.A. 84, 378-382], we found that trypsin had no effect on malonyl-CoA sensitivity. Even when 80% of activity was destroyed by trypsin, there was no difference in the malonyl-CoA sensitivity of the enzyme remaining. Trypsin caused release of the intermembrane-space enzyme adenylate kinase, indicating loss of integrity of the mitochondrial outer membrane, whereas Nagarse and papain caused no release of that enzyme. Citrate synthase was not released by any of the three proteinases, indicating no damage to the mitochondrial inner membrane. When we examined the effects of proteolysis on the inhibition of carnitine palmitoyltransferase by a wide variety of inhibitors having different mechanisms of inhibition, we found differential proteolytic effects that were specific for those inhibitors (malonyl-CoA and hydroxyphenylglyoxylate) that have their inhibitory potencies diminished by changes in physiological state. Both of those inhibitors protected carnitine palmitoyltransferase from the effects of proteolysis, but did not inhibit the proteinases directly. Inhibition by two other inhibitors (DL-2-bromopalmitoyl-CoA and N-benzyladriamycin 14-valerate) was not altered by proteinase treatment, even when most of the enzyme activity had been destroyed. Inhibition by glyburide, which is minimally affected by physiological state, was affected only to a slight extent at the highest concentration of trypsin tested. Proteolysis by Nagarse appeared to produce loss of co-operativity in malonyl-CoA inhibition. The effects of proteolysis are discussed and compared with changes in Ki occurring with changing physiological states.
Kashfi
K
K
Department of Pharmacology, College of Medicine, University of Tennesse, Memphis 38163.
Cook
G A
GA
D000263:Adenylate Kinase / Q000378:metabolism; D000818:Animals; D002334:Carnitine O-Palmitoyltransferase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002950:Citrate (si)-Synthase / Q000378:metabolism; D010450:Endopeptidases / Q000494:pharmacology*; D006038:Glyoxylates / Q000494:pharmacology; D007425:Intracellular Membranes / Q000201:enzymology; D007700:Kinetics; D008297:Male; D008316:Malonyl Coenzyme A / Q000494:pharmacology; D008930:Mitochondria, Liver / Q000187:drug effects / Q000201:enzymology*; D010171:Palmitoyl Coenzyme A / Q000494:pharmacology; D010206:Papain / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013381:Subtilisins / Q000494:pharmacology; D014357:Trypsin / Q000494:pharmacology
C046844:2-bromopalmitoyl coenzyme A; D006038:Glyoxylates; C030921:4-hydroxyphenylglyoxylic acid; D010171:Palmitoyl Coenzyme A; D008316:Malonyl Coenzyme A; D002334:Carnitine O-Palmitoyltransferase; D002950:Citrate (si)-Synthase; D000263:Adenylate Kinase; D010450:Endopeptidases; D013381:Subtilisins; D014357:Trypsin; D010206:Papain